Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
- In-licensing
- View
Inflammation/autoimmune commercialized drugs
Palau Pharma is seeking an inflammation/autoimmune disorder commercialized drug with novel DDT, combination product
Full description
Palau Pharma is seeking a commercialized drug with novel DDT, combination product that is indicated for inflammation and autoimmune disorders. The company would prefer the drug to be orally delivered but would consider topical or transdermal.
These drugs should have strong patent protection and can be developed from the pre-clinical stage through to Phase II stage.
Development status
Preclinical
Type of business relationship sought
Licensing or acquisition of an inflammation/autoimmune disorder commercialized drug.
Licensing contact
Heidi Sisniega
Head
Business Development & Licensing
Head
Business Development & Licensing
Company details
Palau Pharma (Spin-out of Grupo Uriach)
PALAU PHARMA is a newly created biopharmaceutical company devoted to the discovery and development of small molecules for the treatment of inflammatory and autoimmune conditions.
PALAU PHARMA is a newly created biopharmaceutical company devoted to the discovery and development of small molecules for the treatment of inflammatory and autoimmune conditions.
Related reports
Are you looking for reports related to this particular subject. Our Reports section is the best place to start.
Related items
- NCE's - Small molecules indicated for inflammation/autoimmune disorders
- NCEs, new patented formulations and products
- Biologic Entities in clinical development, registered, novel or bio-generic/follow on.
- Esmolol, Cyclosporine, Ketoprofen & Tramadol injections
- Partners/companies looking for a strategic partnership to give them privileged access to hospital markets in Europe.
Related categories
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us